Skip to main content

CRP Utility in COPD Exacerbations

Jul 11, 2019 9:15 am

NEJM reports on the utility of C-reactive protein (CRP) testing in chronic obstructive pulmonary disease (COPD) patients, showing that CRP guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use.

This multicenter, open-label, randomized, controlled trial involving COPD patients in England and Wales. Patients were randomized to usual care versus CRP point-of-care testing (CRP-guided group) in the assessment and management of acute exacerbations of COPD.

Of the 653 patients studied, fewer patients in the CRP-guided group reported antibiotic use than in the usual-care group (57.0% vs. 77.4%; adjusted odds ratio, 0.31; 95% confidence interval [CI], 0.20 to 0.47).

A lower percentage of patients in the CRP-guided group than in the usual-care group received an antibiotic prescription at the initial consultation (47.7% vs. 69.7%; OR 0.31) and during the first 4 weeks of follow-up (59.1% vs. 79.7%; OR 0.30).

CRP-guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use and with no evidence of harm. 

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×